G1 Therapeutics buy Ackermann
Start price
24.06.24
/
0%
€1.06
Target price
24.06.25
-
Performance (%)
72.61%
End price
24.06.24
€1.82
Summary
This prediction ended on 24.06.24 with a price of €1.82. The BUY prediction by Ackermann for G1 Therapeutics saw massive gains of 72.61%. This prediction was marked as speculative and is excluded from Ackermann's performance statistics.G1 Therapeutics is a biopharmaceutical company that focuses on the discovery, development, and commercialization of small molecule therapeutics for the treatment of cancer. Their lead product candidate, Trilaciclib, is designed to improve the outcomes of chemotherapy by preserving hematopoietic stem cells and immune system function. G1 Therapeutics is also developing therapeutics for lung cancer, glioblastoma multiforme, and other solid tumors. The company went public in May 2017 and is listed on the NASDAQ exchange under the symbol GTHX.
Performance without dividends (%)
| Name | 1w |
|---|---|
| G1 Therapeutics | -8.856% |
| iShares Core DAX® | 0.238% |
| iShares Nasdaq 100 | -0.304% |
| iShares Nikkei 225® | 2.271% |
| iShares S&P 500 | -0.296% |
According to Ackermann what are the pros and cons of G1 Therapeutics for the foreseeable future?
Pros
Capable Management
Good culture
Could be worthwhile Investment >10% per year
Cons
Few uniques
Comments by Ackermann for this prediction
In the thread G1 Therapeutics diskutieren
Buy G1 Therapeutics